The NIH spends more on CVS than Cancer. https://report.nih.gov/categorical_spending.aspx

IMHO it is likely that if we get a deal it will with one of thes SGLT2 or DPP4 comanies  as  results in terms of MACE and CHF pevention are confined to certain drugs and if this combination proves superior it will help  sales in a very competitive market. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959222/

I would imagine in this highr risk group of pateints with a better designed trial quantifiable results should be obtainable in a years time.